menu
    • menu

    Company profile for LAPIX Therapeutics

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    LAPIX is an immune system modulation company with 2 distinct therapeutic pipelines; LAPIX-IO and LAPIX-TI. LAPIX-IO replaces multiple checkpoint inhibitors with a single standalone product delivered orally. LAPIX-TI is an alternative to the wrecking ball approach of immunosuppressants. LAPIX-TI has applications in the treatment of auto-immune disorders as well as tolerance induction for gene therapy and enzyme replacement th...
    LAPIX is an immune system modulation company with 2 distinct therapeutic pipelines; LAPIX-IO and LAPIX-TI. LAPIX-IO replaces multiple checkpoint inhibitors with a single standalone product delivered orally. LAPIX-TI is an alternative to the wrecking ball approach of immunosuppressants. LAPIX-TI has applications in the treatment of auto-immune disorders as well as tolerance induction for gene therapy and enzyme replacement therapy.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    LAPIX TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    75 Kneeland St, 14th Floor Boston, MA 02111
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.lapixtherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/lapix-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lapix Doses LPX-TI641 in First Atopic Dermatitis Patient
    Lapix Doses LPX-TI641 in First Atopic Dermatitis Patient

    23 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/23/3209790/0/en/LAPIX-Therapeutics-Announces-First-Patient-Dosed-in-Phase-Ib-Study-of-LPX-TI641-in-Atopic-Dermatitis.html

    GLOBENEWSWIRE
    23 Dec 2025
    Share Share
    LAPIX Doses First Patient For Rheumatoid And Psoriatic Arthritis
    LAPIX Doses First Patient For Rheumatoid And Psoriatic Arthritis

    23 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/23/3014360/0/en/LAPIX-Therapeutics-Doses-First-Patient-In-Phase-1b-Clinical-Trial-of-LPX-TI641-for-Rheumatoid-Arthritis-RA-and-Psoriatic-Arthritis-PsA.html

    GLOBENEWSWIRE
    23 Jan 2025
    Share Share
    Lapix Therapeutics Announces Positive Phase 1 Data For LPX-TI641
    Lapix Therapeutics Announces Positive Phase 1 Data For LPX-TI641

    20 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/20/2984711/0/en/LAPIX-Therapeutics-Announces-Positive-Topline-Phase-1-Clinical-Data-Results-with-LPX-TI641-for-the-Treatment-of-Autoimmune-Diseases.html

    GLOBENEWSWIRE
    20 Nov 2024
    Share Share
    LAPIX Therapeutics Strengthens Board of Directors
    LAPIX Therapeutics Strengthens Board of Directors

    07 Feb 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/02/07/2825233/0/en/LAPIX-Therapeutics-Strengthens-Board-of-Directors-with-Appointments-of-Pharmaceutical-Industry-Veterans-Henry-A-McKinnell-Ph-D-Anthony-Gibney-and-Francisco-Leon-MD-Ph-D.html

    GLOBENEWSWIRE
    07 Feb 2024
    Share Share
    LAPIX Announces First Subjects Dosed in its First-in-Human Study of LPX-TI641
    LAPIX Announces First Subjects Dosed in its First-in-Human Study of LPX-TI641

    07 Nov 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/11/07/2775104/0/en/LAPIX-Therapeutics-Inc-Announces-First-Subjects-Dosed-in-its-First-in-Human-Clinical-Study-of-its-Treg-expanding-Tim3-4-Agonist-LPX-TI641-to-Treat-Multiple-Sclerosis-and-other-Auto.html

    GLOBENEWSWIRE
    07 Nov 2023
    Share Share
    LAPIX Announces FDA Clearance of IND Application for Tim3/4 Agonist LPX-TI641
    LAPIX Announces FDA Clearance of IND Application for Tim3/4 Agonist LPX-TI641

    18 Sep 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/09/18/2744820/0/en/LAPIX-Therapeutics-Inc-Announces-FDA-Clearance-of-IND-Application-for-its-Treg-expanding-Tim3-4-Agonist-LPX-TI641-to-Treat-Multiple-Sclerosis.html

    GLOBENEWSWIRE
    18 Sep 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search